1. Home
  2. OPTX vs EDIT Comparison

OPTX vs EDIT Comparison

Compare OPTX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Syntec Optics Holdings Inc.

OPTX

Syntec Optics Holdings Inc.

HOLD

Current Price

$7.29

Market Cap

261.0M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.63

Market Cap

310.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPTX
EDIT
Founded
1981
2013
Country
United States
United States
Employees
159
N/A
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.0M
310.9M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
OPTX
EDIT
Price
$7.29
$2.63
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$5.30
AVG Volume (30 Days)
1.0M
1.2M
Earning Date
03-31-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.64
52 Week Low
$1.18
$1.43
52 Week High
$12.20
$4.54

Technical Indicators

Market Signals
Indicator
OPTX
EDIT
Relative Strength Index (RSI) 44.90 38.80
Support Level $6.45 $2.42
Resistance Level $8.80 $2.76
Average True Range (ATR) 0.86 0.21
MACD -0.15 -0.06
Stochastic Oscillator 25.70 5.67

Price Performance

Historical Comparison
OPTX
EDIT

About OPTX Syntec Optics Holdings Inc.

Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: